JP2023508173A5 - - Google Patents
Info
- Publication number
- JP2023508173A5 JP2023508173A5 JP2022539175A JP2022539175A JP2023508173A5 JP 2023508173 A5 JP2023508173 A5 JP 2023508173A5 JP 2022539175 A JP2022539175 A JP 2022539175A JP 2022539175 A JP2022539175 A JP 2022539175A JP 2023508173 A5 JP2023508173 A5 JP 2023508173A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody according
- antibody
- seq
- cancer
- fgfr2b
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2019/127903 | 2019-12-24 | ||
| CN2019127903 | 2019-12-24 | ||
| PCT/CN2020/138591 WO2021129656A1 (en) | 2019-12-24 | 2020-12-23 | Novel anti-fgfr2b antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023508173A JP2023508173A (ja) | 2023-03-01 |
| JP2023508173A5 true JP2023508173A5 (enExample) | 2024-01-05 |
| JP7686000B2 JP7686000B2 (ja) | 2025-05-30 |
Family
ID=76573701
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022539175A Active JP7686000B2 (ja) | 2019-12-24 | 2020-12-23 | 新規抗ＦＧＦＲ２ｂ抗体 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230052256A1 (enExample) |
| EP (1) | EP4081539A4 (enExample) |
| JP (1) | JP7686000B2 (enExample) |
| KR (1) | KR20220119143A (enExample) |
| CN (1) | CN114901687A (enExample) |
| AR (1) | AR120884A1 (enExample) |
| AU (1) | AU2020410863A1 (enExample) |
| CA (1) | CA3160811A1 (enExample) |
| MX (1) | MX2022007960A (enExample) |
| TW (1) | TWI861325B (enExample) |
| WO (1) | WO2021129656A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119110806A (zh) * | 2022-03-28 | 2024-12-10 | 杭州中美华东制药有限公司 | 新型抗fgfr2抗体 |
| CN117917435A (zh) * | 2022-10-21 | 2024-04-23 | 北京天广实生物技术股份有限公司 | 结合fgfr2b的抗体及其用途 |
| CN121039158A (zh) * | 2023-03-31 | 2025-11-28 | 杭州中美华东制药有限公司 | 新型抗fgfr2抗体 |
| WO2024240107A1 (zh) * | 2023-05-19 | 2024-11-28 | 广东东阳光药业股份有限公司 | 一种抗fgfr2抗体及其应用 |
| JP2026508860A (ja) * | 2024-01-05 | 2026-03-13 | ビーワン メディシンズ ワン ゲーエムベーハー | 抗ＦＧＦＲ２ｂ抗体、コンジュゲート、及び使用方法 |
| WO2026007196A1 (zh) * | 2024-07-02 | 2026-01-08 | 安博泰克药业有限公司 | 特异性结合FGFR2b的抗体及其与药物的缀合物 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6852703B1 (en) * | 1997-06-04 | 2005-02-08 | Oxford Biomedica (Uk) Limited | Tumor targeted vector |
| NZ542306A (en) * | 2003-03-14 | 2008-04-30 | Wyeth Corp | Antibodies against human IL-21 receptor and uses therefor |
| WO2005035753A1 (ja) * | 2003-10-10 | 2005-04-21 | Chugai Seiyaku Kabushiki Kaisha | 機能蛋白質を代替する二重特異性抗体 |
| EP2060270A3 (en) * | 2003-10-16 | 2009-12-09 | Imclone LLC | Fibroblast growth factor receptor-1 inhibitors and methods of treatment thereof |
| CA2572289A1 (en) * | 2004-06-30 | 2006-08-17 | Centocor, Inc. | Anti-mcp-1 antibodies, compositions, methods and uses |
| US8101721B2 (en) * | 2006-06-15 | 2012-01-24 | Fibron Ltd. | Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof |
| HUE035700T2 (en) * | 2008-11-07 | 2018-05-28 | Galaxy Biotech Llc | Monoclonal antibodies to Fibroblast Growth Factor receptor 2 |
| RU2014109038A (ru) * | 2011-08-23 | 2015-09-27 | Рош Гликарт Аг | Антитела к хондроитинсульфат протеогликану меланомы |
| AR088941A1 (es) * | 2011-11-23 | 2014-07-16 | Bayer Ip Gmbh | Anticuerpos anti-fgfr2 y sus usos |
| SG11201403085PA (en) * | 2011-12-14 | 2014-10-30 | Seattle Genetics Inc | Fgfr antibody drug conjugates (adcs) and the use thereof |
| KR102516152B1 (ko) * | 2013-08-01 | 2023-03-31 | 파이브 프라임 테라퓨틱스, 인크. | 비푸코실화된 항-ｆｇｆｒ２ｉｉｉｂ 항체 |
| CA2961439A1 (en) * | 2014-11-05 | 2016-05-12 | Genentech, Inc. | Anti-fgfr2/3 antibodies and methods using same |
| MX2018006181A (es) * | 2015-11-23 | 2018-09-24 | Five Prime Therapeutics Inc | Inhibidores de fgfr2 solos o en combinacion con agentes que estimulan el sistema inmunitario en el tratamiento contra el cancer. |
| FI3380522T3 (fi) * | 2015-11-25 | 2024-01-16 | Visterra Inc | Vasta-ainemolekyylejä april-proteiinille ja niiden käyttöjä |
| EP3544998A1 (en) * | 2016-11-22 | 2019-10-02 | Merck Patent GmbH | Monoclonal antibody directed to fgfr1 |
| WO2018095932A1 (en) * | 2016-11-22 | 2018-05-31 | Merck Patent Gmbh | Monoclonal antibody directed to fgfr1 |
| KR20220119144A (ko) * | 2019-12-24 | 2022-08-26 | 디잘 (지앙수) 파마슈티칼 씨오., 리미티드 | 신규한 항fgfr2b 항체 |
| KR20220119471A (ko) * | 2019-12-24 | 2022-08-29 | 디잘 (지앙수) 파마슈티칼 씨오., 리미티드 | 신규한 항fgfr2b 항체 |
-
2020
- 2020-12-23 JP JP2022539175A patent/JP7686000B2/ja active Active
- 2020-12-23 KR KR1020227025531A patent/KR20220119143A/ko active Pending
- 2020-12-23 AU AU2020410863A patent/AU2020410863A1/en active Pending
- 2020-12-23 MX MX2022007960A patent/MX2022007960A/es unknown
- 2020-12-23 CN CN202080089840.3A patent/CN114901687A/zh active Pending
- 2020-12-23 CA CA3160811A patent/CA3160811A1/en active Pending
- 2020-12-23 AR ARP200103629A patent/AR120884A1/es unknown
- 2020-12-23 US US17/788,730 patent/US20230052256A1/en active Pending
- 2020-12-23 WO PCT/CN2020/138591 patent/WO2021129656A1/en not_active Ceased
- 2020-12-23 EP EP20907461.6A patent/EP4081539A4/en active Pending
- 2020-12-24 TW TW109145974A patent/TWI861325B/zh active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023508174A5 (enExample) | ||
| JP2023509402A5 (enExample) | ||
| JP2023508173A5 (enExample) | ||
| CN110627906B (zh) | 抗pd-l1/4-1bb双特异性抗体及其用途 | |
| JP7820383B2 (ja) | グリピカン－３およびｔ細胞受容体を標的とする免疫グロブリン単一可変ドメインを含むポリペプチド | |
| RU2749110C2 (ru) | Новый полипептид с аффинностью к PD-L1 | |
| JP7821159B2 (ja) | Ｂｃｍａと結合する単一可変ドメイン及び抗原結合分子 | |
| JP2024500920A5 (enExample) | ||
| CA2959671C (en) | Anti-ck8 antibodies for use in the treatment of cancers | |
| JP2024001073A5 (enExample) | ||
| CN119173540A (zh) | 多特异性抗体及其用途 | |
| CN121909212A (zh) | 抗cdh17抗体及其用途 | |
| CA3208368A1 (en) | Vegfa-binding molecules | |
| AU2020326590A1 (en) | Materials and methods for polymeric antibody receptor targeting | |
| JP7821161B2 (ja) | Ｂｃｍａと結合する単一可変ドメイン及び抗原結合分子 | |
| JP2022505144A5 (enExample) | ||
| CN112823168A (zh) | 结合her2的四聚体多肽 | |
| CN117304324A (zh) | 结合Claudin 18.2的结合部分及其应用 | |
| CN120383678A (zh) | 识别磷脂酰肌醇蛋白聚糖3多个不同表位的抗体及其应用 | |
| CN120271715A (zh) | 抗体及其药物偶联物和用途 | |
| CN120379695A (zh) | 使用Multabody治疗化疗抗性肿瘤 | |
| WO2025117871A1 (en) | Bispecific tetravalent antibody targeting her2 and her3 | |
| WO2025117872A1 (en) | Bispecific antibody-like protein and methods of making and using thereof | |
| JP2024535691A5 (enExample) | ||
| CN116917331A (zh) | 包含靶向磷脂酰肌醇蛋白聚糖-3和t细胞受体的免疫球蛋白单可变结构域的多肽 |